Early Phase 1 Lymphoma Trial, Recruiting (NCT05921253)

Early Phase 1 Lymphoma Trial, Recruiting NCT05921253 Sponsor: University of Oklahoma Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT05921253 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People over 18 years old who have received a type of chemotherapy called anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
People who also meet at least one of the following additional conditions: have had previous radiation treatment to the chest area; are over 50 years old; have type 2 diabetes; have high blood pressure; currently smoke; have a body mass index (BMI) of 30 or higher (classified as obese); have previously had a heart attack; have established heart disease related to artery blockages or significant heart valve problems; or have chronic kidney disease

Who may not be able to join:

People whose heart rhythm is controlled by an atrial pacemaker
People who have a history of seizures and are currently receiving treatment for them
People who have a history of vasovagal syncope (a condition where fainting occurs due to a sudden drop in heart rate and blood pressure)
People with end-stage liver or kidney disease (meaning the liver or kidneys are in the most severe stage of failure)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Tarun W. Dasari, MD, MPH, University of Oklahoma

Phone: 4052718777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05921253

Sponsor: University of Oklahoma

Phase: Early Phase 1

Status: Recruiting

Condition: Lymphoma

Trial contact: 4052718777

More information: https://clinicaltrials.gov/study/NCT05921253

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People over 18 years old who have received a type of chemotherapy called anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
People who also meet at least one of the following additional conditions: have had previous radiation treatment to the chest area; are over 50 years old; have type 2 diabetes; have high blood pressure; currently smoke; have a body mass index (BMI) of 30 or higher (classified as obese); have previously had a heart attack; have established heart disease related to artery blockages or significant heart valve problems; or have chronic kidney disease

Who may not be able to join:

People whose heart rhythm is controlled by an atrial pacemaker
People who have a history of seizures and are currently receiving treatment for them
People who have a history of vasovagal syncope (a condition where fainting occurs due to a sudden drop in heart rate and blood pressure)
People with end-stage liver or kidney disease (meaning the liver or kidneys are in the most severe stage of failure)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Early Phase 1

Sponsor

University of Oklahoma

Registry

ClinicalTrials.gov

Start date

1 December 2023

Est. completion

1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effects of low-level tragus stimulation (LLTS) on global longitudinal strain (GLS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov